Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Peers Fall To Jaw-dropping Valuations And Sell-off, India's Zydus Cadila Bets On JV To Co-exist

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Large companies with well-oiled manufacturing skills and marketing networks in the growing Indian market have demonstrated their attractiveness as buyout targets for multinational companies, but analysts suggest that there could also be a significant interest developing from both sides of the spectrum in signing up proportionately profitable joint ventures for building strong manufacturing assets

You may also be interested in...



Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Billion In Sales By 2015

Cadila is said to have allocated $20 million for its Vermont-headquartered unit Zydus Technologies to work on a range of compounds to be delivered via transdermal patches.

Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Billion In Sales By 2015

Cadila is said to have allocated $20 million for its Vermont-headquartered unit Zydus Technologies to work on a range of compounds to be delivered via transdermal patches.

Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Bil In Sales By 2015

AHMEDABAD, India - In a few months India's Zydus Cadila will join a handful of elite Indian companies like Dr. Reddy's and Cipla that managed to surpass the magic $1 billion mark in annual sales. Cadila says it has a comprehensive blueprint ready to cruise to $3 billion by 2015

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel